New research suggests restoring stellate cells to their healthy and protective state could simultaneously reduce liver scarring and improve liver function.

The global rise in obesity and type 2 diabetes is fueling an epidemic of MASLD and MASH, now recognized as the leading cause of liver-related complications.

Liver fibrosis is a major global health concern, developing as a result of chronic liver diseases (CLDs) such as viral ...

When mothers eat a diet high in fat and sugars, their unborn babies can develop liver stress that continues into early life.

Until now, doctors knew hepatic stellate cells mainly as drivers of liver fibrosis. The actual functions of this cell type have hardly been studied to date. Researchers have now determined that ...

The number one unmet need is that we don't have a good handle on who's at risk, because patients generally don't have too ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD) ...

Hepatic steatosis, often triggered by non-alcoholic fatty liver disease (NAFLD), is a leading cause of liver dysfunction globally, affecting approximately 30% of the population.

Mechanistically, icosabutate improved fibrosis independent of reductions ... ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 metabolic dysfunction-associated steatohepatitis (MASH ...